keyword
https://read.qxmd.com/read/38532238/pharmacological-basis-of-differences-in-dose-response-dose-equivalence-and-duration-of-action-of-inhaled-corticosteroids
#1
JOURNAL ARTICLE
Peter T Daley-Yates, Bhumika Aggarwal, Maximilian Plank
INTRODUCTION: Asthma treatment guidelines classify inhaled corticosteroid (ICS) regimens as low, medium, or high dose. However, efficacy and safety are not independently assessed accordingly. Moreover, differences in ICS duration of action are not considered when a dose regimen is selected. We investigated the efficacy and safety implications of these limitations for available ICS molecules. METHODS: Published pharmacodynamic and pharmacokinetic parameters were used, alongside physiological and pharmacological principles, to estimate the efficacy and safety of available ICS molecules...
March 27, 2024: Advances in Therapy
https://read.qxmd.com/read/38501316/clinical-efficacy-of-montelukast-sodium-combination-therapy-for-cough-variant-asthma-in-children-a-meta-analysis
#2
REVIEW
Shihai Yang, Xia He, Rixia Zhang
This meta-analysis aims to assess the clinical effectiveness of combination therapy with montelukast sodium for the treatment of cough variant asthma (CVA) in children, intending to provide clinical evidence and data to guide the selection of clinical therapy. A literature review was conducted using numerous databases, including China National Knowledge Infrastructure (CNKI), Wanfang database, Embase, PubMed, and Web of Science, from inception to December 2023. Trials meeting the criteria for the combined treatment of montelukast sodium for CVA in children were included...
March 19, 2024: Pediatric Pulmonology
https://read.qxmd.com/read/38488853/efficacy-and-safety-of-once-daily-vilanterol-fluticasone-furoate-mdi-in-persistent-asthma-phase-3-od-inhale-study
#3
JOURNAL ARTICLE
Avdhesh Kumar, Manish Kumar Jain, Vijaykumar Bhagwan Barge, Raghumanda Sunil Kumar, Neeraj Gupta, Harendra Yadav, Amitava Pal, Vivek Eknath Redkar, Asish Mondal, Rahul Kumar Rathore, Pavankumar Daultani, Ashok Jaiswal, Ravi T Mehta
Introduction: Once-daily inhalers have been shown to improve adherence leading to lesser discontinuation compared to twice- or thrice-daily inhalers in management of asthma. Combination of Vilanterol and Fluticasone Furoate (VI/FF) is approved for management of asthma and COPD and is available as a dry powder inhaler. Pressurized-Metered Dose Inhalers (pMDIs) offer ease-of-use and therapy alternatives for patients with low inspiratory flow. This study assessed the efficacy and safety of a new once-daily pMDI containing VI/FF in individuals diagnosed with persistent asthma...
March 15, 2024: Journal of Asthma
https://read.qxmd.com/read/38485149/ers-ebmt-clinical-practice-guideline-on-treatment-of-pulmonary-chronic-graft-versus-host-disease-in-adults
#4
JOURNAL ARTICLE
Saskia Bos, John Murray, Monia Marchetti, Guang-Shing Cheng, Anne Bergeron, Daniel Wolff, Clare Sander, Akshay Sharma, Sherif M Badawy, Zinaida Peric, Agnieszka Piekarska, Joseph Pidala, Kavita Raj, Olaf Penack, Samar Kulkarni, Molly Beestrum, Andrea Linke, Matthew Rutter, Courtney Coleman, Thomy Tonia, Hélène Schoemans, Daiana Stolz, Robin Vos
Chronic graft- versus -host disease (cGvHD) is a common complication after allogeneic haematopoietic stem cell transplantation, characterised by a broad disease spectrum that can affect virtually any organ. Although pulmonary cGvHD is a less common manifestation, it is of great concern due to its severity and poor prognosis. Optimal management of patients with pulmonary cGvHD is complicated and no standardised approach is available.The purpose of this joint European Respiratory Society and European Society for Blood and Marrow Transplantation Task Force was to develop evidence-based recommendations regarding the treatment of pulmonary cGvHD phenotype bronchiolitis obliterans syndrome in adults...
March 14, 2024: European Respiratory Journal
https://read.qxmd.com/read/38477950/comparing-budesonide-and-fluticasone-propionate-in-children-with-moderate-to-severe-asthma-a-pilot-randomized-controlled-trial
#5
RANDOMIZED CONTROLLED TRIAL
Mansour Sadeghzadeh, Parisa Khoshnevisasl, Akefeh Ahmadiafshar, Nima Motamed, Azadeh Pourmarjani
The aim of asthma treatment is to reduce airway inflammation by avoiding environmental triggers and using daily anti-inflammatory medications. This study aimed to compare the effects of fluticasone propionate (FP) and budesonide (Bud) on the clinical symptoms and control of asthma in children with moderate to severe asthma. In this open-label study, children with moderate to severe asthma were randomly selected to receive either FP 250 mcg or Bud 400 mcg for 3 months. Asthma control test scores were measured in both groups monthly...
December 28, 2023: Iranian Journal of Allergy, Asthma, and Immunology
https://read.qxmd.com/read/38470381/allergic-rhinitis-a-review
#6
JOURNAL ARTICLE
Jonathan A Bernstein, Joshua S Bernstein, Richika Makol, Stephanie Ward
IMPORTANCE: Allergic rhinitis affects an estimated 15% of the US population (approximately 50 million individuals) and is associated with the presence of asthma, eczema, chronic or recurrent sinusitis, cough, and both tension and migraine headaches. OBSERVATIONS: Allergic rhinitis occurs when disruption of the epithelial barrier allows allergens to penetrate the mucosal epithelium of nasal passages, inducing a T-helper type 2 inflammatory response and production of allergen-specific IgE...
March 12, 2024: JAMA
https://read.qxmd.com/read/38460609/regional-lung-targeting-with-a-fluticasone-salmeterol-aerosol-using-a-bolus-breath-hold-method-of-the-preciseinhale%C3%A2-system-a-first-evaluation-in-humans
#7
JOURNAL ARTICLE
Per Gerde, Carl-Olof Sjöberg, Helen Bäckroos, Joakim Englund, Marit Wangheim, Helena Litorp
BACKGROUND: In development of inhaled drugs- and formulations the measured concentration in the systemic circulation is often used as a surrogate for local dosimetry in the lungs. To further elucidate regional differences in the fate of drugs in the lungs, different aerodynamic sizes of aerosols have been used to target major airway regions. An alternative approach to achieve regional targeting of aerosols, is to use a defined aerosol bolus together with a bolus breath hold strategy. A small volume of test aerosol is intercalated and stopped at different penetration depths, to achieve increased drug deposition at chosen lung locations...
March 7, 2024: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38452834/critical-attributes-of-fine-excipient-materials-in-carrier-based-dry-powder-inhalation-formulations-the-particle-shape-and-surface-properties
#8
JOURNAL ARTICLE
Mustafa M A Elsayed, Iman M Alfagih, Katrina Brockbank, Alhassan H Aodah, Raisuddin Ali, Khaled Almansour, Ahmed O Shalash
The potential of fine excipient materials to improve the aerodynamic performance of carrier-based dry powder inhalation (DPI) formulations is well acknowledged but not fully elucidated. To improve the understanding of this potential, we studied two fine excipient materials: micronized lactose particles and silica microspheres. Inhalation formulations, each composed of a coarse lactose carrier, one of the two fine excipient materials (0.0-15.0 % w/w), and a spray-dried drug (fluticasone propionate) material (1...
March 5, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38446336/association-between-increased-risk-of-pneumonia-with-ics-in-copd-a-continuous-variable-analysis-of-patient-factors-from-the-impact-study
#9
JOURNAL ARTICLE
Bhumika Aggarwal, Paul Jones, Alejandro Casas, Mauro Gomes, Siwasak Juthong, Diego Litewka, Bernice Ong-Dela Cruz, Alejandra Ramirez-Venegas, Abdullah Sayiner, James van Hasselt, Chris Compton, Lee Tombs, Stephen Weng, Gur Levy
INTRODUCTION: Despite the proven benefits of inhaled corticosteroid (ICS)-containing triple therapy for chronic obstructive pulmonary disease (COPD), clinicians limit patient exposure to ICS due to the risk of pneumonia. However, there are multiple factors associated with the risk of pneumonia in patients with COPD. This post hoc analysis of IMPACT trial data aims to set the risks associated with ICS into a context of specific patient-related factors that contribute to the risk of pneumonia...
March 6, 2024: Pulmonary Therapy
https://read.qxmd.com/read/38419021/the-effect-of-combining-an-inhaled-corticosteroid-and-a-long-acting-muscarinic-antagonist-on-human-airway-epithelial-cells-in-vitro
#10
JOURNAL ARTICLE
Maria Gabriella Matera, Barbara Rinaldi, Cecilia Calabrese, Carmela Belardo, Luigino Calzetta, Mario Cazzola, Clive Page
BACKGROUND: Airway epithelial cells (AECs) are a major component of local airway immune responses. Direct effects of type 2 cytokines on AECs are implicated in type 2 asthma, which is driven by epithelial-derived cytokines and leads to airway obstruction. However, evidence suggests that restoring epithelial health may attenuate asthmatic features. METHODS: We investigated the effects of passive sensitisation on IL-5, NF-κB, HDAC-2, ACh, and ChAT in human bronchial epithelial cells (HBEpCs) and the effects of fluticasone furoate (FF) and umeclidinium (UME) alone and in combination on these responses...
February 28, 2024: Respiratory Research
https://read.qxmd.com/read/38395664/dangers-and-therapeutic-difficulties-of-intracranial-hemangioma-in-infants-a-care-case-report
#11
JOURNAL ARTICLE
Léa Fath, François Simon, Raphaël Levy, Olivia Boccara, Vincent Couloigner
INTRODUCTION: Description of neurological complications induced by intracranial hemangioma in infants and by the initiation of beta-blocker treatment (propranolol). OBSERVATION: A 2-month-old infant was referred for grade 5 non-congenital unilateral peripheral facial palsy. Work-up revealed ipsilateral profound hearing loss and two intracranial hemangiomas: one in the ipsilateral internal auditory canal (IAC), the other in the cerebellum opposite the nodule of vermis...
February 22, 2024: European Annals of Otorhinolaryngology, Head and Neck Diseases
https://read.qxmd.com/read/38381542/real-world-users-of-triple-therapy-for-asthma-in-the-us
#12
JOURNAL ARTICLE
Nadia N Hansel, Carl B Abbott, Carlyne M Averell, Guillaume Germain, François Laliberté, Malena Mahendran, Mei S Duh, Russell A Settipane
OBJECTIVES: For patients with asthma who remain symptomatic on a medium-dose inhaled corticosteroid/long-acting β2 agonist, addition of a long-acting muscarinic antagonist as a supplementary controller is a recommended option. However, real-world data on the characteristics and treatment patterns of these patients are limited. This study described the demographics and clinical characteristics of new users of single- or multiple-inhaler triple therapy and treatment patterns preceding triple-therapy initiation...
February 2024: American Journal of Managed Care
https://read.qxmd.com/read/38371642/eosinophilic-oesophagitis-in-a-nigerian-adolescent-a-case-report
#13
Ikobah Joanah Moses, Ikwuagwu Elekwachi, Ita Ukpabio, Theophilus Ugbem, Omeodu Chimankpan Okechukwu, Emmanuel Ekanem
Eosinophilic oesophagitis (EoE) is a chronic immune and antigen-mediated disease characterized by symptoms related to oesophageal dysfunction, and histologically, is marked by eosinophilic infiltrate in the oesophageal mucosa. It is prevalent in developed countries and considered rare in developing countries. There is an interplay of allergic and genetic factors in the aetiology of EoE. This is a report of EoE in a 15-year-old female adolescent in Nigeria who presented to the University of Calabar Teaching Hospital with recurrent vomiting, abdominal pain, weight loss, and dysphagia...
2024: Pan African Medical Journal
https://read.qxmd.com/read/38362679/preparation-optimization-and-in-vitro-characterization-of-fluticasoneloaded-mixed-micelles-based-on-stearic-acid-g-chitosan-as-a-pulmonary-delivery-system
#14
JOURNAL ARTICLE
Shima Tasharoie, Seyed Naser Ostad, Mohsen Amini, Reyhaneh Sabourian, Kambiz Gilani
PURPOSE: The primary objective of this study was to optimize formulation variables and investigate the in vitro characteristics of fluticasone propionate (FP)-loaded mixed polymeric micelles, which were composed of depolymerized chitosan-stearic acid copolymer (DC-SA) in combination with either tocopheryl polyethylene glycol succinate or dipalmitoylphosphatidylcholine for pulmonary drug delivery. METHODS: A D-optimal design was employed for the optimization procedure, considering lipid/ polymer ratio, polymer concentration, drug/ polymer ratio, and lipid type as independent variables...
February 15, 2024: Recent advances in drug delivery and formulation
https://read.qxmd.com/read/38351402/an-observational-study-to-determine-the-real-life-effectiveness-of-mp-azeflu-%C3%A2-in-austrian-patients-with-persistent-allergic-rhinitis
#15
JOURNAL ARTICLE
Katharina Marth, Andreas Renner, Georg Langmayr, Wolfgang Pohl, Duc Tung Nguyen, Hans Christian Kuhl
BACKGROUND: Many patients with allergic rhinitis (AR) have moderate-to-severe persistent AR. Meda Pharma's AzeFlu (MP-AzeFlu® ) is an intranasal AR treatment comprising a novel formulation of azelastine hydrochloride and fluticasone propionate in a single device. METHODS: This prospective observational study of 214 adults and adolescents in Austria with moderate-to-severe persistent AR assessed the effectiveness of MP-AzeFlu (one spray/nostril twice daily; daily doses: azelastine hydrochloride 548 μg; and fluticasone propionate 200 μg) for AR control in clinical practice using the visual analog scale...
February 13, 2024: Drugs—Real World Outcomes
https://read.qxmd.com/read/38318884/bayesian-or-frequentist-there-is-no-question-when-comparing-single-inhaler-triple-therapies-via-network-meta-analysis-focus-on-fluticasone-furoate-umeclidinium-vilanterol-fixed-dose-combination-in-chronic-obstructive-pulmonary-disease
#16
REVIEW
Luigino Calzetta, Paola Rogliani
OBJECTIVES: Single-inhaler triple therapies (SITT) have never been directly compared in randomized controlled trials (RCTs) in chronic obstructive pulmonary disease (COPD). Cochrane recommends the Bayesian approach for indirect comparisons but a frequentist network meta-analysis (NMA) reported superiority of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) over other SITT. We assessed the most appropriate inference method for NMA characterized by between-study heterogeneity on SITT in COPD...
February 6, 2024: Expert Review of Respiratory Medicine
https://read.qxmd.com/read/38310193/outcomes-of-patients-with-copd-treated-with-ics-laba-before-and-after-initiation-of-single-inhaler-triple-therapy-with-fluticasone-furoate-umeclidinium-vilanterol-ff-umec-vi
#17
JOURNAL ARTICLE
Meredith McCormack, Rosirene Paczkowski, Noelle N Gronroos, Stephen G Noorduyn, Lydia Lee, Phani Veeranki, Mary G Johnson, Emmeline Igboekwe, Kristin Kahle-Wrobleski, Reynold Panettieri
INTRODUCTION: Triple therapy (fluticasone furoate/umeclidinium/vilanterol; FF/UMEC/VI) has been shown to improve symptoms and reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. This real-world study compared exacerbation rates and healthcare resource utilization (HCRU) before and after initiation of FF/UMEC/VI in patients with COPD previously treated with inhaled corticosteroid (ICS)/long-acting β2 -agonist (LABA). METHODS: This retrospective cohort study included commercial and Medicare Advantage with Part D administrative claims data from September 01, 2016, to March 31, 2020, of patients diagnosed with COPD...
February 4, 2024: Advances in Therapy
https://read.qxmd.com/read/38309696/baseline-characteristics-and-ics-lama-laba-response-in-asthma-analyses-from-the-captain-study
#18
JOURNAL ARTICLE
Louis-Philippe Boulet, Carl Abbott, Guy Brusselle, Dawn Edwards, John Oppenheimer, Ian D Pavord, Emilio Pizzichini, Hironori Sagara, David Slade, Michael E Wechsler, Peter G Gibson
BACKGROUND: Findings from CAPTAIN (NCT02924688) suggest treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) differs according to baseline type 2 (T2) inflammation markers in patients with moderate-to-severe asthma. Understanding how other patient physiologic and clinical characteristics affect response to inhaled therapies may guide physicians toward a personalized approach for asthma management. OBJECTIVE: To investigate, using CAPTAIN data, the predictive value of key demographic and baseline physiologic variables in patients with asthma (lung function, bronchodilator reversibility, age, age at asthma onset) on response to addition of the long-acting muscarinic antagonist UMEC to inhaled corticosteroid/long-acting β2 -agonist combination FF/VI, or doubling FF dose...
February 1, 2024: Journal of Allergy and Clinical Immunology in Practice
https://read.qxmd.com/read/38298997/retracted-biochemical-behaviours-of-salmeterol-fluticasone-propionate-in-treating-asthma-and-chronic-obstructive-pulmonary-diseases-copd
#19
Emergency Medicine International
[This retracts the article DOI: 10.1155/2022/2593740.].
2024: Emergency Medicine International
https://read.qxmd.com/read/38297180/prescribing-practices-of-inhaled-corticosteroids-for-premature-infants-in-the-neonatal-intensive-care-unit
#20
JOURNAL ARTICLE
Monica Tang, Anna Ibrahim, Christopher Laughon, Kaila Moore, Angibel Tejada, Dean Tran, Ryan Kilpatrick, Rachel G Greenberg, Christoph P Hornik, Kanecia Zimmerman, Matthew M Laughon, Reese H Clark, Jason E Lang
OBJECTIVE: Despite limited safety and efficacy data, inhaled corticosteroids (ICS) are prescribed to premature infants in the neonatal intensive care unit (NICU). We examined contemporary use and risk factors for ICS use in the NICU. STUDY DESIGN: Infants <33 weeks gestational age and <1500 gm birth weight discharged from Pediatrix Medical Group NICUs between 2010 and 2020 were included. We evaluated the association between ICS prescription and clinical characteristics using univariable and multivariable logistic regression...
January 31, 2024: Journal of Perinatology: Official Journal of the California Perinatal Association
keyword
keyword
30179
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.